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Strengths and limitations of this study
 ► This will be the largest study assessing robust data 
collected over 20 years across multiple jurisdictions 
in Australia, and will provide data beyond the limita-
tions of current studies exploring births for parents 
with end- stage kidney disease.
 ► Renal registers lack detailed pregnancy data, while 
the perinatal data sets lack information about kidney 
disease, thus by linking these two data sets we will 
be able to evaluate pregnancy outcomes and perina-
tal risk factors associated with adverse outcomes in 
individuals with end- stage kidney disease.
 ► One of the novel aspects of this study is the method 
of linking fathers receiving dialysis or with a kidney 
transplant to the mothers and their babies within the 
perinatal data sets, using the birth register, enabling 
the identification of family units.
 ► Population data sets may inherently have inaccura-
cies. Birth register paternity data may not reflect bi-
ological paternity; therefore, some assumptions will 
be made regarding the biological paternity.
AbStrACt
Introduction Achieving parenthood is challenging in 
individuals receiving renal replacement therapy (RRT; dialysis 
or kidney transplantation) for end- stage kidney disease. 
Decision- making regarding parenthood in RRT recipients 
should be underpinned by robust data, yet there is limited 
data on parental factors that drive adverse health outcomes. 
Therefore, we aim to investigate the perinatal risks and 
outcomes in parents receiving RRT.
Methods and analysis This is a multijurisdictional 
probabilistic data linkage study of perinatal, hospital, birth, 
death and renal registers from 1991 to 2013 from New South 
Wales, Western Australia, South Australia and the Australian 
Capital Territory. This study includes all babies born ≥20 
weeks’ gestation or 400 g birth weight captured through 
mandated data collection in the perinatal data sets. Through 
linkage with the Australian and New Zealand Dialysis and 
Transplant (ANZDATA) registry, babies exposed to RRT 
(and their parents) will be compared with babies who have 
not been exposed to RRT (and their parents) to determine 
obstetric and fetal outcomes, birth rates and fertility rates. 
One of the novel aspects of this study is the method that will 
be used to link fathers receiving RRT to the mothers and their 
babies within the perinatal data sets, using the birth register, 
enabling the identification of family units. The linked data 
set will be used to validate the parenthood events directly 
reported to ANZDATA.
Ethics and dissemination Ethics approval was obtained 
from Human Research Ethics Committees (HREC) and 
Aboriginal HREC in each jurisdiction. Findings of this study 
will be disseminated at scientific conferences and in peer- 
reviewed journals in tabular and aggregated forms. De- 
identified data will be presented and individual patients will 
not be identified. We will aim to present findings to relevant 
stakeholders (eg, patients, clinicians and policymakers) to 
maximise translational impact of research findings.
IntroduCtIon
Chronic kidney disease affects around 10% 
of the adults in the world1 and up to about 
3% of pregnant women.2 3 Within Australia, 
among 25 652 individuals receiving renal 
replacement therapy (RRT; dialysis or kidney 
transplantation) for end- stage kidney disease 
(ESKD) at the end of 2018, 16% were in 
their reproductive age (18 to 44 years); 1760 
women and 2397 men.4 These individuals 
may have to consider significant and complex 
issues surrounding parenthood and preg-
nancy while receiving RRT.
For women receiving RRT, pregnancies are 
relatively uncommon and medically compli-
cated.5 Fertility rates are considerably lower 
in women receiving RRT than the general 
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population, particularly in women receiving dialysis; rates 
are improved, although not normalised, following kidney 
transplantation.6–13 These pregnancies face higher risks 
of adverse outcomes for mothers and babies; notably, 
pre- eclampsia, hypertension, prematurity and low birth 
weight.6 8 10 14
The fate of infants born to women receiving RRT 
remains poorly defined during the perinatal period. 
Maternal factors (including comorbidities) and models 
of antenatal care are likely to be important determinants 
of pregnancy outcomes, yet there is little robust data 
on such factors with which to make informed decisions. 
There is also, as yet, lack of linkage between perinatal 
and renal data, as the Renal registers collect very limited 
pregnancy data, while the perinatal data sets lack infor-
mation about maternal kidney disease. Therefore, having 
a linked data set containing both perinatal and renal data 
is important to aid exploration of outcomes and drivers 
of events.
Men receiving RRT are similarly subjected to impaired 
fertility, sperm production and lower sperm quality,15 16 
likely due to the uraemic environment. This commences 
in earlier stages of kidney disease and is not improved 
by dialysis.17–19 Although fertility is largely restored post- 
transplantation, the long- term use of immunosuppres-
sive medications (eg, mycophenolic acid) may have an 
impact on sperm production.20 Currently, there is very 
limited data available about the outcomes of pregnan-
cies fathered by men receiving dialysis,21 22 with more 
data available for males after transplantation.23–28 A key 
concern with individuals after kidney transplantation is 
the potential fetotoxic effects of immunosuppressive 
medications.29 Previous studies have reported no negative 
impact on fertility or fetal outcomes with paternal myco-
phenolic acid exposure23 24 or in males after kidney trans-
plantation.25 Despite this, there are still uncertainties in 
counselling about the use of mycophenolate derivatives 
in men considering parenthood.
Several previous studies within the Australia and New 
Zealand Dialysis and Transplant (ANZDATA) registry 
have evaluated parenthood outcomes in female kidney 
transplant recipients. A study by Levidiotis et al assessing 
maternal and transplant survival rates following a live 
birth in female transplant recipients, from 1966 to 2005, 
found equivalent rates to non- pregnant women with a 
functioning transplant.8 In this study, a decline in the 
absolute fertility rates over time in female transplant 
recipients was identified.8 This was postulated to be 
due to counselling against pregnancy, impaired fertility 
and early pregnancy loss not reported to ANZDATA. A 
similar study by Wyld et al assessing parenthood events 
in female transplant recipients from 1971 to 2005 iden-
tified lower average gestational age, lower average birth 
weight and lower perinatal survival rate in babies born 
to mothers post- kidney transplantation compared with 
the general Australian population.10 These pregnancies 
were also complicated by high rates of pre- eclampsia 
(30%). However, the majority of the pregnancies 
resulted in live birth.8 In both of the studies above, live 
birth rates significantly improved over time, the rate of 
surgical terminations declined and the number of still-
births and spontaneous abortions remained constant.8 10 
The perinatal mortality rate was six times higher in this 
cohort of female transplant recipients compared with 
the general Australian population. The rate of congen-
ital abnormalities in transplant recipients was similar 
to the population rate (3% to 5%), although this may 
be an underestimation in the context of voluntary 
reporting.10 13
Several other studies within the ANZDATA registry have 
evaluated parenthood outcomes in women receiving dial-
ysis. In contrast to transplant recipients, pregnancy rates 
in women receiving dialysis increased over time, partic-
ularly from 1996 to 2008.6 This may be due to intensive 
dialysis treatment and other improvements in medical 
and obstetric care. Live birth rates were lower in women 
receiving dialysis (~60%), compared with transplant recip-
ients, although this gap narrowed after the exclusion of 
early terminations (~75%).6 7 High rates of pre- eclampsia 
(19.4%) were noted in women receiving dialysis. The 
majority of the babies born to women receiving dialysis 
were preterm (<37 weeks’ gestation) (53%) and had a 
low birth weight (65%).6 7 Women who conceived prior to 
commencing dialysis had higher live birth rates compared 
with those who conceived after starting dialysis (91% vs 
63%), while the babies had similar distribution of gesta-
tional age and birth weight. This was postulated to be 
due to better residual renal function (higher estimated 
glomerular filtration rate at chronic dialysis commence-
ment) in the cohort who commenced dialysis during 
pregnancy.
There are concerns regarding the reporting of parent-
hood events to the ANZDATA registry, due to the volun-
tary nature of reporting, that need to be explored through 
comparisons with the legislated perinatal data sets. While 
it is possible to establish birth outcomes, fetal adverse 
events (eg, intrauterine growth restriction) and maternal 
medical complications (eg, pre- eclampsia), obstetric 
and perinatal data that is essential in understanding 
these outcomes is limited within the ANZDATA registry, 
although it is available in state- based perinatal data sets.
Studies that have explored perinatal outcomes for 
individuals with ESKD to date have been limited. Addi-
tional clinical data is required for better identification 
of risk factors for the higher rates of adverse outcomes 
previously identified. Outcomes for twin babies, causes 
underlying perinatal deaths and long- term outcomes 
of preterm babies born to parents receiving RRT still 
remain to be investigated. Obtaining information about 
babies of fathers who received RRT is valuable, however, 
ANZDATA registry does not collect data on mothers (not 
receiving RRT) for paternity parenthood events, nor does 
it follow- up the babies of parents receiving RRT in the 
long- term. To overcome these challenges, we will conduct 
a data linkage between a number of data sets including 
the ANZDATA registry and state- based perinatal data sets.
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Aims and hypotheses
The aim of this study is to explore the association of 
RRT with pregnancy outcomes, antenatal and perinatal 
outcomes, compared with the non- RRT population.
1. Fertility, birth rates and paternity rates: To report birth 
rates and fertility rates of mothers receiving RRT com-
pared with mothers who have either never received 
RRT or have given birth prior to commencement of 
RRT, and paternity rates of fathers receiving RRT.
2. Validation of ANZDATA parenthood data collection: 
To compare parenthood events identified through the 
data linkage to those directly reported to the ANZDA-
TA registry.
3. Maternal outcomes: To quantify the excess mater-
nal risks for pregnancies such as maternal morbidity 
during pregnancy, labour and birth, maternal resource 
utilisation in women receiving RRT compared with 
women who have never received RRT and those who 
are receiving RRT without pregnancy.
4. Fetal outcomes: To investigate the effect of maternal 
or paternal ESKD requiring RRT on perinatal and 
health of neonates such as birth status, prematurity, 
birth weight, neonatal intensive care unit admission, 
length of hospital stay and congenital anomalies.
5. RRT and parenthood: To evaluate parental factors spe-
cific to RRT which may be important determinants of 
outcome for babies born to parents receiving RRT.
We hypothesised higher rates of maternal morbidity 
in women receiving RRT compared with the women 
who have never received RRT during pregnancy. It is 
thought that babies of men receiving RRT will have better 
outcomes than babies born to women receiving RRT, and 
similar to the general population.
MEthodS And AnAlySIS
Study design
This study is a retrospective cohort study that uses state- 
level data linkage of records from 01 January 1991 to 
31 December 2013 from perinatal, hospital, emergency, 
birth, death and renal register data (ANZDATA) in New 
South Wales (NSW), Western Australia (WA), South 
Australia (SA) and the Australian Capital Territory (ACT). 
Follow- up data will be available for all babies beyond 31 
December 2013 and up until the latest data set available 
at the time of data linkage.
Study population and inclusion criteria
The study population includes all babies born at least 20 
weeks’ gestation or 400 g birth weight between 01 January 
1991 and 31 December 2013, captured within the peri-
natal data sets from each jurisdiction, except for NSW 
and ACT where the perinatal data sets are only available 
from 01 January 1994 and 01 January 1997, respectively. 
Within the study population, all babies born to women 
after commencement of RRT will be identified as the 
maternal RRT birth cohort, while all other babies born 
to mothers who have either never received RRT or have 
given birth prior to commencement of RRT will be 
identified as the maternal non- RRT birth cohort. Some 
women within the maternal RRT birth cohort may have 
conceived prior to commencing dialysis. Transplantation 
does not occur during pregnancy. Babies fathered by 
men after commencement of RRT will be identified as 
the paternal RRT birth cohort and analysed separately. 
If the father was not receiving RRT at conception (based 
on calculated/estimated conception date), the baby will 
be in the paternal non- RRT birth cohort. The ANZDATA 
registry collects information from all patients receiving 
RRT where the intention to treat is long- term. This study 
defines receiving RRT as those patients with RRT treat-
ments reported to ANZDATA. The ANZDATA registry 
does not collect cases of RRT for acute kidney injury 
that resolves. Pregnancies in ANZDATA females will 
be identified through named linkage to perinatal data 
sets. Babies born to ANZDATA males will be identified 
through named linkage to birth registers. The mothers 
associated with babies of ANZDATA males will be flagged 
within the non- RRT birth cohort to allow family units to 
be identified. Early pregnancy loss including miscarriage 
or termination of pregnancy <20 weeks’ gestation are not 
captured in the perinatal data sets.
Key outcomes of interest
Maternal outcomes
1. General obstetric complications and maternal comor-
bidity during pregnancy (gestational hypertension, 
pre- eclampsia, eclampsia, gestational diabetes, ante-
partum/postpartum haemorrhage, placental abrup-
tion and praevia).
2. Labour and birth outcomes (type of onset of labour, 
indication for induction, type of birth, elective caesar-
ean section, indication for caesarean section, analge-
sia administered, complications of labour, transfusion 
post partum).
3. Maternal resource utilisation methods (admissions 
during antenatal period, hospital length of stay im-
mediately pre- delivery and post- delivery, maternal 
readmission within 4 weeks post- delivery, place of 
birth, mode of hospital separation, intensive care unit 
admission).
Fetal/neonatal outcomes
1. Birth outcomes (Birth status (live birth vs stillbirth), 
neonatal and perinatal deaths, neonatal intensive care 
unit admission, gestational age and its categories, birth 
weight and its categories).
2. Infant outcomes (Activity, pulse, grimace, appearance 
and respiration (APGAR) scores, resuscitation at birth, 
neonatal morbidity, length of hospital stay, readmis-
sion and congenital anomalies).
linked data sets
Third party linkage units (table 1) will perform the 
probabilistic linkage of records (figure 1) based on 
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Table 1 Summary of perinatal data sets by different states in Australia
State Perinatal data collection
Numbers of births 1991–2013 
(approximately) Years for linkage Linkage unit
NSW NSW PDC 1 900 000 1994–2013 CHeReL
ACT ACT PDC 100 000 1997–2013 CHeReL
WA WA Midwives’ Notification System 630 000 1991–2013 Data linkage WA
SA SA Perinatal Statistics Collection 440 000 1991–2013 SA/NT Datalink
ACT, Australian Capital Territory; CHeReL, Centre for Health Record Linkage; NSW, New South Wales; NT, Northern Territory; PDC, perinatal 
data collection; SA, South Australia; WA, Western Australia.
Figure 1 Data sets to be linked. ANZDATA, Australia and 
New Zealand Dialysis and Transplant registry; NICU, neonatal 
intensive care units; NSW, New South Wales; RRT, renal 
replacement therapy.
name, date of birth and postcode and generate de- iden-
tified project master linkage keys for each matched 
record.
Perinatal data
Data on pregnancy and childbirth are reported to the 
perinatal data sets in each jurisdiction in Australia, by 
midwives and other birth attendants. Data collection is 
mandated for all births ≥20 weeks’ gestation or ≥400 g 
birth weight. Data on demographic information of the 
mother and baby, models of antenatal care, pregnancy 
outcomes, maternal comorbidities during pregnancy, 
labour and birth outcomes, maternal resource utilisa-
tion and fetal outcomes are collected. Perinatal data sets 
are different and independent in each jurisdiction. The 
maternity information matrix has identified similar data 
items collected across each jurisdiction and this will be 
used for pooling data for analysis.30
ANZDATA registry
Established in 1977 from existing dialysis and transplant 
registers with data collections from 1963, ANZDATA 
receives clinical data annually for patients receiving 
RRT from all renal units in Australia and New Zealand 
with follow- up reporting rates for the annual survey 
approaching 100%. The ANZDATA registry introduced 
a specific parenthood form in 2001 to formalise data 
collection on parenthood events in both males and 
females receiving RRT, which has been expanded to 
include additional clinical questions for the 2019 survey. 
It is one of the largest registers in the world, with more 
than 2000 pregnancies reported since the inception of the 
register, and more than 1000 pregnancies and more than 
900 live births reported during 1991 to 2013. Importantly, 
ANZDATA captures all pregnancy events including those 
ending <20 weeks’ gestation. The ANZDATA parenthood 
form enables the collection of data on maternal compli-
cations of diabetes and pre- eclampsia and pregnancy 
outcomes including early terminations and stillbirths, 
gestational age, birth weight, presence or absence of fetal 
abnormality and neonatal mortality, but only limited data 
is available. The cohort of men and women who ever 
received RRT during 1970 to 2016 will be linked to peri-
natal data sets.
Births and deaths registers
Data sets that register details of all births and deaths in 
each jurisdiction will be used for identification of the 
birth cohort and analysis of death rates. Birth register will 
enable the identification of family units by linking fathers 
receiving RRT to babies and their mothers.
Hospital separation and admitted patient data
This data set captures hospital attendance and diagnostic 
coding data from all mothers and babies admitted to 
hospitals for treatment during pregnancy and after birth. 
Comorbidity and health events in the perinatal period 
and also following childbirth can be evaluated, through 
admission rates and diagnostic codes attributed to these 
admissions.
Emergency department data
This data set captures emergency department presenta-
tions with disease codes and enables evaluation of the 
overall healthcare burden for babies born to mothers 
receiving RRT.
Neonatal intensive care units (NSW only)
This data set collects short- term and neurodevelopmental 
data for neonates admitted to neonatal intensive care 
units within 28 days of birth and enables comparisons 
of adverse events, treatments and outcomes between 
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Table 2 Summary of obstetric, maternal and infant 
variables of interest
Variables of interest
Demographic characteristics  ► Age at conception
 ► Ethnicity
 ► Primary renal disease
 ► Socio- economic 
indexes for areas
 ► Smoking status
 ► Total duration of RRT
 ► Duration of latest 
modality of RRT
 ► Body mass index
 ► Pre- existing diabetes 
and hypertension
Antenatal factors  ► Parity
 ► Previous caesarean 
section
 ► Gestational age at 
first antenatal visit
 ► Number of antenatal 
visits
 ► Types of antenatal 
tests
Fetal variables  ► Plurality
 ► Sex of baby
RRT, renal replacement therapy
neonates born to mothers receiving RRT and other 
preterm neonates.
Births defects register
This is a register that collects details of congenital anom-
alies at birth. Birth defects registers from SA and WA will 
be used for this study. For NSW and ACT, birth defects 
registers will not be used as data is only available for a 
small 5- year window, instead the admitted patient data 
captures the birth defect information more accurately for 
these jurisdictions. This data will enable us to determine 
if there is a higher rate of birth defects and congenital 
conditions in neonates born to mothers receiving RRT.
Comparator cohort
The comparator cohort includes all babies born to mothers 
who have either never received RRT or have given birth 
prior to commencement of RRT, captured within the peri-
natal data sets from each jurisdiction. Some of the events 
investigated in this study are very uncommon or rare in 
the general cohort, but clinically relevant and thought to 
be statistically different in the RRT birth cohort. There-
fore, the entire comparator cohort is required to avoid 
introducing any selection bias. The planned analyses will 
require different control cohorts (much smaller subset of 
the full control cohort) for comparison, depending on 
the endpoint being evaluated and risk factors for that 
endpoint, therefore a single sampling of the maternal 
non- RRT birth cohort is unlikely to be representative.
Patient and public involvement
Our previous systematic review31 and interview study31 
established the perspectives and preferences of women 
with chronic kidney disease. Women thought parenthood 
is a priority but causes significant decisional conflict and 
guilt, exacerbated by medical catastrophising.31 From 
this we developed a framework for pregnancy counsel-
ling, with shared decision- making forming the central 
tenet of care.31 Leading on from this prior work we 
have established a national consumer advisory group in 
Australia consisting of six women with kidney disease. 
This consumer advisory group have provided and will 
continue to provide us insights into their lived experi-
ences and real- world issues most relevant to them and 
their families. They can also raise awareness and advocate 
about consumer priorities. In the future, this consumer 
advisory group will provide feedback on written work, 
assist us in preparing consumer friendly summaries for 
dissemination of key research findings into the commu-
nity and develop future research questions.
Planned statistical analysis
Descriptive techniques, relative risks of variables, survival 
(time- to- event) analysis with survival curves and mortality 
trends for high- risk infants will be used. Excess risk will 
be determined by calculation of standardised incidence 
ratios. Multivariate analysis will determine odds ratio/
relative risk of maternal and perinatal outcomes, adjusted 
for parental demographic and RRT- related parameters 
such as parental age, comorbidities and era of treatment. 
The effects of multiple births by a single parent will be 
accounted for using multilevel mixed effect models. 
Outcomes for the RRT and non- RRT birth cohorts will 
be compared via standard techniques (χ2 tests, Student’s 
t- test, Fisher’s exact tests, multivariate logistic regression 
and linear regression) as appropriate. Analyses will be 
performed using Stata V.16.0. Detailed analysis plan is 
outlined below and variables of interest are summarised 
in table 2.
Analysis 1 and 2
The number of births to parents in the RRT and non- 
RRT birth cohorts will be quantified. The RRT cohort will 
be divided into different treatment modalities (dialysis 
or transplant) at time of conception. Parents receiving 
haemodialysis or peritoneal dialysis at conception will be 
defined as the dialysis RRT birth cohort, while parents 
with a functioning kidney transplant at conception will 
be defined as the transplant RRT birth cohort. Birth 
outcome (live birth, stillbirth or neonatal death) for each 
cohort will be described using descriptive statistics. Crude 
birth rate, age- specific fertility rates and age- specific 
paternity rates for each cohort will be calculated using 
the equations below and will be compared between the 
RRT and non- RRT birth cohorts.
 Crude birth rates =
(
Total no: of births (Live and stillbirth)in each cohort
Total population in each cohort
)
× 1000 
 Age − specific fertility rates =
(
No:of live births to women in each age group
Estimated population of women in each age group
)
× 1000 
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 Age − specific paternity rates =
(
No:of live births to men in each age group
Estimated population of men in each age group
)
× 1000 
Total fertility rates (the average number of live births 
per woman) will be calculated as a sum of 5- year age- 
specific fertility rates per 1000 women (live births at each 
age of women per female population of that age). The 
3- yearly moving average of fertility rates will be also calcu-
lated from fertility rates in the current year, previous year 
and next year. Each parenthood event identified from the 
data linkage will be validated with the parenthood events 
directly reported to ANZDATA to identify any parent-
hood events not reported to ANZDATA directly and to 
identify any potential linkage errors.
The population estimates for the RRT birth cohort 
during 1991 to 2013 will be obtained from ANZDATA, as 
this will be the total number of patients receiving RRT in 
each jurisdiction during this time period. The population 
estimates for the non- RRT birth cohort will be calculated 
as the total population of each jurisdiction during 1991 to 
2013 from the Australian Bureau of Statistics less the RRT 
population from each jurisdiction.
Analysis 3
The excess risks for pregnancies in women receiving RRT, 
compared with the non- RRT group, will be quantified by 
evaluating pregnancy outcomes; antenatal events and 
delivery complications; events contributing to preterm 
delivery; short- term postpartum obstetric, medical and 
surgical events and complications and outcomes including 
hospital length of stay, rates of readmission and reasons 
for readmission by calculation of standardised incidence 
ratios. Multivariate analysis will be used to determine 
odds ratio/relative risk of outcomes of interests listed 
above, with adjustments for parental demographic and 
RRT- related parameters such as parental age, comorbidi-
ties and era of treatment.
The long- term morbidity burden of mothers with 
ESKD including hospitalisations will be assessed using 
multivariate logistic regression, adjusting for potential 
confounding factors such as maternal age and era of 
treatment. The pregnancy outcomes and morbidity in 
women receiving RRT will be compared with women 
who have never received RRT using a multivariate logistic 
regression, with adjustments for maternal age and era of 
treatment.
Analysis 4
The relationship of parental RRT with perinatal and 
health of babies will be analysed by evaluating birth 
status and condition at birth; rates of prematurity, low 
birth weight and small for gestational age; intensive 
care or special care nursery admission data; presence 
and nature of congenital anomalies; hospital admission, 
morbidity and mortality data in the perinatal period and 
to 5 years of age and differences between preterm babies 
born to RRT parents and preterm babies born to non- 
RRT parents using either multivariate linear regression 
(for continuous data) or multivariate logistic regression 
(for categorical data), with adjustments for parental age, 
comorbidities and era of treatment. For each data item 
the denominator will be adjusted to account for the vari-
ation in different data collection periods in different 
registers.
Analysis 5
Parental factors specific to RRT including age, primary 
renal disease, comorbidity, RRT modality, duration of 
therapy, immunosuppressive drug exposure and kidney 
transplant function, which are likely to be important 
determinants of outcome, will be evaluated by estimating 
relative risks using multivariate regression models for the 
outcome of live birth. Analyses will be adjusted for poten-
tial confounding factors such as parental age, era of treat-
ment and comorbidities.
Ethics and dissemination
Ethics approval was obtained from the NSW Population 
and Health Services Human Research Ethics Committee 
(HREC), NSW Aboriginal Health and Medical Research 
Council HREC, Department of Health WA HREC, WA 
Aboriginal Health Ethics Committee, SA Department 
for Health and Wellbeing HREC, SA Aboriginal HREC, 
ACT Health HREC and Calvary Public Hospital HREC. 
De- identified linked data sets will be stored on secure 
servers at the Royal Adelaide Hospital, Adelaide, South 
Australia, with access granted only to research staff. The 
results of this study will be published in peer- reviewed 
journals and presented at scientific conferences. No indi-
vidual participants will be identified or identifiable. All 
data will be analysed and presented in the de- identified 
form. We will aim to present findings to relevant stake-
holders (eg, patients, clinicians and policymakers) to 
maximise translational impact of research findings.
dISCuSSIon
The current study explores the maternal and fetal 
outcomes of parents receiving dialysis or transplant for 
ESKD, compared with the general Australian popula-
tion. For the first time nationally in Australia, this study 
will provide population evidence on the maternal and 
paternal factors, obstetric factors and perinatal risk factors 
associated with adverse pregnancy and fetal outcomes in 
individuals receiving RRT during pregnancy. Improved 
understanding of factors driving adverse outcomes will 
contribute to improving clinical management, especially 
if some factors are preventable.
Despite the strengths of the study, there are some poten-
tial limitations. Since the data used in the study is not 
collected for research purposes, quality and completeness 
may be limited. In addition, birth register paternity data 
may not reflect biological paternity for both the RRT and 
non- RRT birth cohorts. However, a subgroup of fathers 
receiving RRT who have had births also reported to the 
ANZDATA parenthood register will have confirmed 
biological paternity as this is an inclusion criterion for this 
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register. For all other births not reported to ANZDATA, 
assumptions are made regarding the biological paternity. 
With respect to sperm donation as a potential confounder 
for paternity, the data sets in this study will not be able to 
identify offspring from sperm donation. However, these 
events are uncommon, therefore the influence on the 
data is likely to be small. Nonetheless, the current study 
will be one of the first studies to explore perinatal risks 
and outcomes in the Australian population at a national 
level.
Overall, the data obtained from this study will inform 
future health policy and planning for this high- risk 
cohort, to assist clinicians in counselling and better 
managing patients who are considering or are faced with 
parenthood while receiving RRT.
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